EDEN Longevity Market Watcher is currently displaying demonstration data for preview purposes.
Current Limitations:
Expected completion: Q2 2025
| Ticker | Company | Price | 7D % | 30D % | 90D % | EDEN Score | Signal | Reimbursement News |
|---|---|---|---|---|---|---|---|---|
| GILD | Gilead Sciences | $68.45 | +2.3% | -1.2% | +8.7% | 7.2 | Strong | FDA approval for new longevity drug pending Q2 2025 |
| RHHBY | Roche Holding AG | $32.18 | -0.8% | +3.4% | -2.1% | 8.1 | Moderate | Swiss health insurance coverage expanded for prevention programs |
| NVS | Novartis AG | $98.76 | +1.5% | +2.8% | +12.4% | 7.8 | Strong | EU reimbursement framework approved for aging biomarkers |
| JNJ | Johnson & Johnson | $156.23 | +0.9% | -0.5% | +5.3% | 6.9 | Weak | Medicare coverage review for preventive care technologies |
| PFE | Pfizer Inc. | $28.91 | -1.2% | +4.1% | -8.2% | 6.5 | Moderate | Clinical trial results expected for longevity compound |
EDEN Score: Proprietary metric (0-10) combining market position, R&D pipeline strength, reimbursement landscape, and longevity focus. Updated weekly.
Signal Strength: Qualitative assessment based on reimbursement progress, clinical evidence quality, and market adoption indicators.
Data Sources: Financial market APIs, regulatory databases (FDA, EMA, Swissmedic), HTA body reports (NICE, IQWIG, Swiss FOPH), company disclosures.
Update Frequency: Market data refreshes daily; HTA and contract signals updated weekly; comprehensive review monthly.
Disclaimer: For informational purposes only. Not investment advice. Conduct independent due diligence before making investment decisions.
Data sources: Financial Markets APIs, Regulatory Databases, HTA Bodies • Last updated: 10/29/2025, 1:06:45 PM
EDEN Longevity Research • For informational purposes only